ALK CEO on peanut allergy competitors: "They might have been the first, but that does not necessarily mean they are the best"

In 2022, allergy group ALK is initiating a peanut allergy market effort, an area that the companies Aimmune and DBV Technologies have long been targeting. Their results have been less prominent, and all they’re doing is opening the door for more threatening competition, says President and CEO at ALK Carsten Hellmann.

Photo: Gregers Tycho/Ritzau/Ritzau Scanpix

It created a buzz when the allergy group ALK announced in February that it would initiate a massive venture within food allergy, which is a massive market, far bigger than that ALK’s well-trodden territory of respiratory allergies.

On Thursday, the Denmark-based company reported that a phase I trial of a new tablet vaccine technology has been scheduled for the first half of 2022, initially testing it as a peanut allergy vaccine targeting the global market, which is valued around DKK 25bn (USD 2.85bn).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs